We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

New Interim Phase II Clinical Data from the OPAL Study Demonstrate Encouraging Single Agent Response Rates for Tosedostat in Elderly Patients with Relapsed Refractory AML

News   Jun 08, 2011

 
New Interim Phase II Clinical Data from the OPAL Study Demonstrate Encouraging Single Agent Response Rates for Tosedostat in Elderly Patients with Relapsed Refractory AML
 
 
Advertisement
 

RELATED ARTICLES

Phase 1 Clinical Trial of University of Queensland COVID-19 Vaccine Begins

News

The first participants were enrolled into a Phase 1 clinical trial of the University of Queensland’s (UQ) COVID-19 vaccine candidate on July 13.

READ MORE

Hydroxychloroquine Reduces Incidence of Heartbeat Condition in Newborns

News

Researchers show that giving the antimalarial drug hydroxychloroquine to pregnant women who previously had a child affected by congenital heart block reduced the likelihood that the condition recurred in a subsequent pregnancy by 50%.

READ MORE

New Cancer Vaccine Ready for Human Trials

News

A new cancer vaccine, comprised of human antibodies fused with tumor-specific protein, is ready to begin human testing.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE